Intercept Pharma Secures Dismissal of Securities Fraud Claims

Skadden secured the dismissal of all claims against Intercept Pharmaceuticals Inc. and certain of its officers in a putative securities fraud class action alleging that the company misled investors about its liver disease drug Ocaliva.